The Journal of rheumatology · 2025
COVID-19 Vaccine Booster Uptake and Effectiveness Among Persons With Systemic Autoimmune and Rheumatic Diseases.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ziemba Yonah C, Elkin Eric P, Kazemian Elham, Wilson Brigid M, Siddiqui Hinnah, Schleicher Cheryl B, Hsiao Crystal A, Zidar David A, Kushi Lawrence H, Figueiredo Jane C, Skarbinski Jacek, Crawford James M
Аннотация
OBJECTIVE: To assess coronavirus disease 2019 (COVID-19) booster uptake and vaccine effectiveness (VE) in reducing COVID-19 hospitalization in persons with systemic autoimmune and rheumatic diseases (SARDs).
METHODS: Adult patients with SARDs receiving disease-modifying antirheumatic drugs at 4 health systems in the United States were identified retrospectively. Exposures were (1) receipt of an additional dose of monovalent COVID-19 vaccine prior to January 1, 2022, with follow-up to August 31, 2022; and (2) receipt of bivalent COVID-19 vaccine between September 1, 2022 and August 31, 2023.
RESULTS: Among 201,165 patients with SARDs, 126,756 (63%) had received 1 monovalent booster as of January 1, 2022. During 94,842 person-years (PY) of follow-up, the COVID-19 hospitalization rate was 15.6 per 1000 PY among those who had received a monovalent booster vs 20.1 per 1000 PY among those who had not, with an adjusted VE of 38% (95% CI 31-44%) and a number needed to vaccinate of 267 (95% CI 230-325). Among 246,991 patients with SARDs with 233,622 PY of follow-up in the bivalent study period, the COVID-19 hospitalization rate was 7.9 per 1000 PY for the 87,906 (36%) patients who received the bivalent vaccine vs 10.2 per 1000 PY for the patients who did not. The adjusted VE of the bivalent vaccine was 32% (95% CI 24-39%) with a number needed to vaccinate of 617 (95% CI 500-838).
CONCLUSION: COVID-19 booster vaccinations provided significant protection against severe COVID-19 in persons with SARDs. Thus, increasing vaccine uptake should be prioritized in this high-risk immunocompromised population.
METHODS: Adult patients with SARDs receiving disease-modifying antirheumatic drugs at 4 health systems in the United States were identified retrospectively. Exposures were (1) receipt of an additional dose of monovalent COVID-19 vaccine prior to January 1, 2022, with follow-up to August 31, 2022; and (2) receipt of bivalent COVID-19 vaccine between September 1, 2022 and August 31, 2023.
RESULTS: Among 201,165 patients with SARDs, 126,756 (63%) had received 1 monovalent booster as of January 1, 2022. During 94,842 person-years (PY) of follow-up, the COVID-19 hospitalization rate was 15.6 per 1000 PY among those who had received a monovalent booster vs 20.1 per 1000 PY among those who had not, with an adjusted VE of 38% (95% CI 31-44%) and a number needed to vaccinate of 267 (95% CI 230-325). Among 246,991 patients with SARDs with 233,622 PY of follow-up in the bivalent study period, the COVID-19 hospitalization rate was 7.9 per 1000 PY for the 87,906 (36%) patients who received the bivalent vaccine vs 10.2 per 1000 PY for the patients who did not. The adjusted VE of the bivalent vaccine was 32% (95% CI 24-39%) with a number needed to vaccinate of 617 (95% CI 500-838).
CONCLUSION: COVID-19 booster vaccinations provided significant protection against severe COVID-19 in persons with SARDs. Thus, increasing vaccine uptake should be prioritized in this high-risk immunocompromised population.